Sanara MedTech Inc. (NASDAQ:SMTI – Get Rating) – Cantor Fitzgerald upped their FY2023 earnings per share (EPS) estimates for shares of Sanara MedTech in a research report issued on Thursday, May 18th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.21) for the year, up from their previous forecast of ($0.58). The consensus estimate for Sanara MedTech’s current full-year earnings is ($0.21) per share.
Sanara MedTech (NASDAQ:SMTI – Get Rating) last released its quarterly earnings results on Monday, March 20th. The company reported ($0.51) earnings per share for the quarter. The company had revenue of $15.32 million for the quarter. Sanara MedTech had a negative return on equity of 25.60% and a negative net margin of 18.67%.
Sanara MedTech Stock Performance
Institutional Investors Weigh In On Sanara MedTech
Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its holdings in shares of Sanara MedTech by 4.5% during the first quarter. Geode Capital Management LLC now owns 29,362 shares of the company’s stock worth $1,211,000 after purchasing an additional 1,252 shares during the last quarter. Susquehanna International Group LLP boosted its holdings in shares of Sanara MedTech by 66.1% during the first quarter. Susquehanna International Group LLP now owns 25,295 shares of the company’s stock worth $1,043,000 after purchasing an additional 10,068 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Sanara MedTech during the first quarter worth $726,000. Citadel Advisors LLC boosted its holdings in shares of Sanara MedTech by 35.4% during the third quarter. Citadel Advisors LLC now owns 14,832 shares of the company’s stock worth $440,000 after purchasing an additional 3,878 shares during the last quarter. Finally, HRT Financial LP acquired a new stake in shares of Sanara MedTech during the first quarter worth $453,000. Institutional investors and hedge funds own 4.03% of the company’s stock.
Sanara MedTech Company Profile
Sanara MedTech, Incengages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.
- Get a free copy of the StockNews.com research report on Sanara MedTech (SMTI)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.